Since there have been no cases of overdose reported to date, neither signs nor symptoms of overdose have been identified. In a Phase I study doses up to 52 ml of SonoVue were administered to normal volunteers without serious adverse events being reported. In the event of overdose occurring, the patient should be observed and treated symptomatically.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign Out
